Alzheimer's disease, Internal medicine, Pathology, Apolipoprotein E and Dementia are her primary areas of study. The Alzheimer's disease study combines topics in areas such as Biomarker, Cerebrospinal fluid and Immunology. Her Biomarker study combines topics from a wide range of disciplines, such as Amyloid beta and Neuroscience.
Her biological study deals with issues like Oncology, which deal with fields such as Csf biomarkers. Her Apolipoprotein E research is multidisciplinary, relying on both Allele, Transgene, Brain mapping and Degenerative disease. Anne M. Fagan combines subjects such as Occipital lobe and PSEN1 with her study of Dementia.
Her scientific interests lie mostly in Alzheimer's disease, Internal medicine, Disease, Cerebrospinal fluid and Pathology. Her work deals with themes such as Biomarker, Cognition and Dementia, Cognitive decline, which intersect with Alzheimer's disease. Her Biomarker research is multidisciplinary, incorporating perspectives in Hippocampus, Asymptomatic and Neuroimaging.
Her Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Oncology. Her Disease study incorporates themes from Genetics, Clinical trial, Bioinformatics, Psychiatry and Neuroscience. Her Cerebrospinal fluid research includes themes of Positron emission tomography, Single-nucleotide polymorphism, Immunology and Endophenotype.
Anne M. Fagan focuses on Internal medicine, Alzheimer's disease, Biomarker, Disease and Oncology. In her work, Vascular dementia is strongly intertwined with Endocrinology, which is a subfield of Internal medicine. Her Alzheimer's disease research also works with subjects such as
Her research in Biomarker intersects with topics in Cerebrospinal fluid, Neurodegeneration, Neuroimaging, Dementia and Hippocampus. Her Cerebrospinal fluid research is under the purview of Pathology. Anne M. Fagan has researched Disease in several fields, including Neuroscience, Immunology, Atrophy and Bioinformatics.
Her primary scientific interests are in Alzheimer's disease, Biomarker, Cerebrospinal fluid, Internal medicine and Disease. Anne M. Fagan interconnects Clinical trial and Brain mapping in the investigation of issues within Alzheimer's disease. Her biological study spans a wide range of topics, including Csf biomarkers, Pittsburgh compound B, Asymptomatic, Cognitive decline and Apolipoprotein E.
Cerebrospinal fluid is a subfield of Pathology that Anne M. Fagan investigates. Her research integrates issues of Gastroenterology, Endocrinology and Oncology in her study of Internal medicine. Her studies in Dementia integrate themes in fields like Amyloid β and Gene mutation.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling;Paul S. Aisen;Laurel A. Beckett;David A. Bennett.
Alzheimers & Dementia (2011)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Anne M. Fagan;Mark A. Mintun;Robert H. Mach;Sang-Yoon Lee.
Annals of Neurology (2006)
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance
Joseph M. Castellano;Jungsu Kim;Floy R. Stewart;Hong Jiang.
Science Translational Medicine (2011)
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease
David M. Holtzman;Kelly R. Bales;Tanya Tenkova;Anne M. Fagan.
Proceedings of the National Academy of Sciences of the United States of America (2000)
Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults
Anne M. Fagan;Catherine M. Roe;Chengjie Xiong;Mark A. Mintun.
JAMA Neurology (2007)
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease
Richard J. Perrin;Anne M. Fagan;David M. Holtzman.
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging
John C. Morris;Catherine M. Roe;Chengjie Xiong;Anne M. Fagan.
Annals of Neurology (2010)
Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.
Daniel A Nation;Melanie D Sweeney;Axel Montagne;Abhay P Sagare.
Nature Medicine (2019)
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model
John R. Cirrito;Rashid Deane;Anne M. Fagan;Michael L. Spinner.
Journal of Clinical Investigation (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: